PMID- 37114128
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231106
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Treatment options for recurrent platinum-resistant ovarian cancer: A systematic 
      review and Bayesian network meta-analysis based on RCTs.
PG  - 1114484
LID - 10.3389/fonc.2023.1114484 [doi]
LID - 1114484
AB  - BACKGROUND: There are a variety of treatment options for recurrent 
      platinum-resistant ovarian cancer, and the optimal specific treatment still 
      remains to be determined. Therefore, this Bayesian network meta-analysis was 
      conducted to investigate the optimal treatment options for recurrent 
      platinum-resistant ovarian cancer. METHODS: Pubmed, Cochrane, Embase, and Web of 
      Science were searched for articles published until 15 June 2022. The outcome 
      measures for this meta-analysis were overall survival (OS), progression-free 
      survival (PFS), and adverse events (AEs) of Grade 3-4. The Cochrane assessment 
      tool for risk of bias was used to evaluate the risk of bias of the included 
      original studies. The Bayesian network meta-analysis was conducted. This study 
      was registered on PROSPERO (CRD42022347273). RESULTS: Our systematic review 
      included 11 RCTs involving 1871 patients and 11 treatments other than 
      chemotherapy. The results of meta-analysis showed that the overall survival (OS) 
      was the highest in adavosertib + gemcitabine compared with conventional 
      chemotherapy, (HR=0.56,95%CI:0.35-0.91), followed by sorafenib + topotecan 
      (HR=0.65, 95%CI:0.45-0.93). In addition, Adavosertib + Gemcitabine regimen had 
      the highest PFS (HR=0.55,95%CI:0.34-0.88), followed by Bevacizumab + Gemcitabine 
      regimen (HR=0.48,95%CI:0.38-0.60) and the immunotherapy of nivolumab was the 
      safest (HR=0.164,95%CI:0.312-0.871) with least adverse events of Grades 3-4. 
      CONCLUSIONS: The results of this study indicated that Adavosertib (WEE1 
      kinase-inhibitor) + gemcitabine regimen and Bevacizumab + Gemcitabine regimen 
      would be significantly beneficial to patients with recurrent platinum-resistant 
      ovarian cancer, and could be preferred for recurrent platinum-resistant ovarian 
      cancer. The immunotherapeutic agent, Nivolumab, is of considerable safety, with a 
      low risk for grade-III or IV adverse events. Its safety is comparable to 
      Adavosertib + gemcitabine regimen. Pazopanib + Paclitaxel (weekly regimen), 
      Sorafenib + Topotecan/Nivolumab could be selected if there are contraindications 
      of the above strategies. SYSTEMATIC REVIEW REGISTRATION: 
      https://www.crd.york.ac.uk/prospero/, identifier CRD42022347273.
CI  - Copyright (c) 2023 Li, Zou, Wang, Yin, Yan and Liu.
FAU - Li, Juan
AU  - Li J
AD  - Department of Oncology, Guangzhou Panyu District Central Hospital, Guangzhou, 
      China.
FAU - Zou, Guorong
AU  - Zou G
AD  - Department of Oncology, Guangzhou Panyu District Central Hospital, Guangzhou, 
      China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Nursing, Central Hospital of Gansu Province, Lanzhou, China.
FAU - Yin, Chen
AU  - Yin C
AD  - Department of Oncology, Guangzhou Panyu District Central Hospital, Guangzhou, 
      China.
FAU - Yan, Haowen
AU  - Yan H
AD  - Department of Oncology, Guangzhou Panyu District Central Hospital, Guangzhou, 
      China.
FAU - Liu, Shengpeng
AU  - Liu S
AD  - Department of Clinical Medicine, People's Hospital of Weining County, Bijie, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20230411
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10126232
OTO - NOTNLM
OT  - Bayesian network meta-analysis
OT  - blind RCT
OT  - ovarian neoplasms recurrence
OT  - randomized controlled trial
OT  - systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/04/28 06:42
MHDA- 2023/04/28 06:43
PMCR- 2023/01/01
CRDT- 2023/04/28 02:39
PHST- 2022/12/02 00:00 [received]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/04/28 06:43 [medline]
PHST- 2023/04/28 06:42 [pubmed]
PHST- 2023/04/28 02:39 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1114484 [doi]
PST - epublish
SO  - Front Oncol. 2023 Apr 11;13:1114484. doi: 10.3389/fonc.2023.1114484. eCollection 
      2023.